2 weeks Ago By ABMN Staff
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL – Get Free Report ) was up 4.8% during trading on Thursday after Piper Sandler raised their price target on the stock from $15.
00 to $23.00. Piper Sandler currently has a neutral rating on the stock.
Rigel Pharmaceuticals traded as high as $28.90 and last traded at $28.73.
Approximately 100,289 shares were traded during mid-day trading, a decline of 37% from the average daily volume of 160,428 shares. The stock had previously closed at $27.41.
Several other research firms have also commented on RIGL. Cantor Fitzgerald reissued a “neutral” rating and set a $15.00 price objective on shares of Rigel Pharmaceuticals in a research note on Friday, September 20th.
Citigroup raised their price target on Rigel Pharmaceuticals from $40.00 to $49.00 and gave the stock a “buy” rating in a research report on Tuesday.
HC Wainwright reissued a “buy” rating and issued a $57.00 price target on shares of Rigel Pharmaceuticals in a report on Friday, October 25th. Finally, StockNews.
com raised Rigel Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, October 18th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.
com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $31.30. Read Our Latest Research Report on Rigel Pharmaceuticals Institutional Trading of Rigel Pharmaceuticals Rigel Pharmaceuticals Price Performance The company’s 50-day moving average is $15.
85 and its 200-day moving average is $12.24. The firm has a market capitalization of $483.
71 million, a price-to-earnings ratio of 196.14 and a beta of 0.96.
Rigel Pharmaceuticals Company Profile ( Get Free Report ) Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. See Also Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
